FHA
ALNY icon

First Horizon Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

First Horizon Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$61K Buy
187
+63
+51% +$17.4K ﹤0.01% 897
2025
Q1 		$33.5K Hold
124
– – ﹤0.01% 1109
2024
Q4 		$29.2K Buy
124
+29
+31% +$7.63K ﹤0.01% 1189
2024
Q3 		$26.1K Buy
95
+8
+9% +$2.08K ﹤0.01% 1258
2024
Q2 		$21.1K Sell
87
-1
-1% -$158 ﹤0.01% 1252
2024
Q1 		$13.2K Hold
88
– – ﹤0.01% 1488
2023
Q4 		$16.8K Hold
88
– – ﹤0.01% 1393
2023
Q3 		$15.6K Sell
88
-7
-7% -$1.34K ﹤0.01% 1336
2023
Q2 		$18K Sell
95
-4
-4% -$793 ﹤0.01% 1312
2023
Q1 		$19.8K Sell
99
-5
-5% -$1.05K ﹤0.01% 1271
2022
Q4 		$24.7K Sell
104
-7
-6% -$1.49K ﹤0.01% 1182
2022
Q3 		$21K Sell
111
-19
-15% -$3.62K ﹤0.01% 1211
2022
Q2 		$18K Buy
130
+49
+60% +$6.95K ﹤0.01% 1331
2022
Q1 		$13K Buy
81
+12
+17% +$1.83K ﹤0.01% 1010
2021
Q4 		$10K Buy
69
+13
+23% +$2.42K ﹤0.01% 1508
2021
Q3 		$10K Buy
56
+40
+250% +$7.5K ﹤0.01% 1520
2021
Q2 		$2K Sell
16
-7
-30% -$1.02K ﹤0.01% 1728
2021
Q1 		$3K Hold
23
– – ﹤0.01% 1545
2020
Q4 		$2K Buy
23
+7
+44% +$935 ﹤0.01% 1300
2020
Q3 		$2K Sell
16
-66
-80% -$9.38K ﹤0.01% 1294
2020
Q2 		$12K Sell
82
-21
-20% -$2.83K ﹤0.01% 950
2020
Q1 		$11K Buy
+103
New +$11.9K ﹤0.01% 907
2019
Q2 		– Sell
-16
Closed -$1K – 1546
2019
Q1 		$1K Buy
+16
New +$1.34K ﹤0.01% 1464

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Horizon Advisors's ALNY Position: Q2 2025 in Review

First Horizon Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 51% in Q2 2025, buying an estimated $17.4K and bringing the position to 187 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #897.

First Horizon Advisors first reported a position in ALNY in Q1 2019 and has held it in 23 quarters since. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • First Horizon Advisors held 187 shares of Alnylam Pharmaceuticals worth $61K as of Q2 2025.
  • First Horizon Advisors bought 63 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $17.4K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #897 holding.
  • First Horizon Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2019 and has held it in 23 quarters since.
  • 654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.